Karyopharm Therapeutics
KPTI
81 hedge funds and large institutions have $701M invested in Karyopharm Therapeutics in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 8 closing their positions.
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
19% more capital invested
Capital invested by funds: $587M → $701M (+$114M)
14% more funds holding
Funds holding: 71 → 81 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$32M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$16.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$8.81M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.07M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10.4M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$4.43M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.23M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.69M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.48M |
KPTI Hedge Fund Activity: Q4 2014 in Review
81 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2014, worth a combined $701M — up 19% from $587M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KPTI positions and 8 closed out — a net gain of 11 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $32M. The largest seller was PFM Health Sciences, cutting an estimated $10.4M.
- 81 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2014, up from 71 in Q3 2014.
- Funds reported $701M of Karyopharm Therapeutics stock for Q4 2014, up 19% quarter-over-quarter.
- 19 funds opened new Karyopharm Therapeutics positions in Q4 2014 and 8 closed out, a net change of +11 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $32M added.
- The largest Karyopharm Therapeutics seller in Q4 2014 was PFM Health Sciences, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2014.